Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: methotrexate sodium, methotrexate, pemetrexed dipotassium +5 | 1.00 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 4 Parkinson's papers of 4,780 | 0.79 |
| pathways Reactome | 3 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 7799
Sealed predictions
- DHFR in dopamine neurons, braak+0.27 (p 0.489) → +0.02 (p 0.963)receipt 7807
Swarm cases
receipt 7807: DHFR in dopamine neurons, braak
- power
- full sample +0.12 (p 0.646, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.06 (p 0.800, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.12 (p 0.627, n 18). could be the mix.
- skeptic
- leave-one-out range +0.01 to +0.25, sign flips 0; without severely affected donors +0.12 (p 0.646, n 18). fragile.
- cell type
- strongest in OPCs: -0.63 (p 0.0049, n 18) vs +0.12 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DHFR in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up DHFR · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.30 p 0.286 (needs p < 2.7e-4)
Receipts
loading the receipts